Clinical InvestigationIntentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study
Section snippets
Data sources
The JHS is a prospective community-based observational study of 5306 African Americans designed to investigate risk factors for cardiovascular disease.11 Initiated in 2000, all study participants provided written informed consent, and study protocols were approved by local institutional review boards. Participants were recruited from the Jackson, Mississippi cohort of the Atherosclerosis Risk in Communities study and the overall tricounty population.12 Participants completed 3 study visits:
Results
Figure 1 presents the details for the analysis cohort using self-reported adherence data from the baseline exam. Of 2933 participants routinely taking medications at baseline, 2138 (72.9%) reported non-adherence. Of these participants, 754 (35.3%) reported only unintentional non-adherence, 263 (12.3%) reported only intentional non-adherence, and 1121 (52.4%) both intentional and unintentional non-adherence.
Table II presents the baseline characteristics by adherence status. Compared with those
Discussion
Among African Americans in the JHS, more than 70% of participants taking medications for chronic conditions reported non-adherence at baseline, with more than half of those reporting non-adherence having some degree of both intentional and unintentional non-adherence. The number of medications being taken and medication classes were was similar between those reporting and not reporting non-adherence. Factors independently associated with unintentional non-adherence included younger age and
Conclusion
More than 70% of participants taking medications for chronic conditions in the current study reported non-adherence. Approximately half of these participants reported both intentional and unintentional reasons for non-adherence. Specific participant factors and individual medication classes were associated with distinct patterns of intentional and unintentional non-adherence, yet the overall modest discrimination of the models suggests contributions from other factors. These findings provide a
Acknowledgments
The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201300049C and HHSN268201300050C), Tougaloo College (HHSN268201300048C), and the University of Mississippi Medical Center (HHSN268201300046C and HHSN268201300047C) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs and participants of the JHS.
Disclosures
RJM receives research support from the National Institutes of Health (U10HL110312 and R01AG045551-01A1), Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Gilead, Luitpold, Merck, Novartis, and Otsuka. Dr. Daichi Shimbo is a consultant for Abbott Vascular and Novartis Pharmaceuticals Corporation. The remaining authors report no relevant conflicts of interest.
References (23)
- et al.
Medication adherence: WHO cares?
Mayo Clin Proc
(2011) Predictors of medication adherence in the elderly
Clin Ther
(1998)- et al.
Racial differences in medication adherence: A cross-sectional study of Medicare enrollees
Am J Geriatr Pharmacother
(2010) - et al.
Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper
Int J Nurs Stud
(2007) - et al.
Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study
Am J Med Sci
(2004) - et al.
Adherence to cardiovascular medications: lessons learned and future directions
Prog Cardiovasc Dis
(2013) - et al.
Racial differences in blood pressure control: potential explanatory factors
Am J Med
(2006) - et al.
Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications
J Am Coll Cardiol
(2017) - et al.
Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial
JAMA
(2006) - et al.
Adherence to medication
N Engl J Med
(2005)
Patient characteristics associated with medication adherence
Clin Med Res
Cited by (14)
Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: A qualitative study
2020, Blood AdvancesCitation Excerpt :Factors that underlying their decisions vary from experiencing adverse effects17 to their perceptions of the need for the prescribed treatment.18 The concept of intentionality has been used to examine treatment nonadherence among individuals living with a variety of chronic conditions, including coronary heart disease,19-21 glaucoma,22 kidney disease,23 hypertension,20,24 epilepsy,25 and diabetes.21,24 This research has led to tailored interventions, with mixed results, and recommendations that focus on intentional and unintentional nonadherence.24,26-30
American Society of Hematology 2020 guidelines for sickle cell disease: Prevention, diagnosis, and treatment of cerebrovascular disease in children and adults
2020, Blood AdvancesCitation Excerpt :However, pilot studies that applied similar techniques to children with SCD generated positive results.145 Cognitive lapses, which occur most often in individuals with cognitive impairments, and aspect of executive dysfunction (eg, defects in mental flexibility and working memory) are the most common cause of poor adherence to medical therapies in the general population.146-148 Functional assessments of executive function can both identify deficits and inform interventions by determining what types of cues patients need while completing multistep activities (Figure 3 in supplemental File 5).149,150
Medication adherence trajectory of patients with chronic diseases and its influencing factors: A systematic review
2024, Journal of Advanced NursingUnderstanding multi-level barriers to medication adherence among adults living with sickle cell disease
2023, Medicine (United States)
Funding: This work was supported by grant R01HL117305, K24 HL125704 and R01HL117323 from the National Heart, Lung, And Blood Institute. The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. The authors thank the participants and data collection staff of the Jackson Heart Study. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.